Research programme: sordarin antifungals - Diversa

Drug Profile

Research programme: sordarin antifungals - Diversa

Alternative Names: DVSA 103; DVSA 105; DVSA 106; DVSA 107; DVSA 108; DVSA 109

Latest Information Update: 14 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Diversa
  • Class Indenes
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 31 Jan 2006 Discontinued - Preclinical for Mycoses in USA (unspecified route)
  • 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Mycoses antimicrobial activity section ,
  • 01 Mar 2004 Diversa's sordarins research programme is available for partnering in Asia (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top